Startseite Kongressberichte & Archiv 23rd Congress of EHA Important Lymphoma Presentations

S154 RELEVANCE: PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA

Author(s): Frank Morschhauser, et al. ABSTRACT

Conclusion
RELEVANCE is the first randomized phase III trial comparing the chemotherapy-free regimen R2 v standard R-chemo followed by rituximab maintenance in previously untreated patients with FL. The superiority of R2over R-chemo was not demonstrated in this phase III trial, however, compared with R-chemo, R2 appeared to show similar efficacy with a different toxicity profile.

 

See also webcast presentation from press briefing